Enzalutamide Plus Androgen Deprivation Therapy (Adt) Versus Flutamide Plus Adt In Men With Castration-Resistant Prostate Cancer (Crpc): Aftercab

Hiroji Uemura,Kazuki Kobayashi,Akira Yokomizo,Shiro Hinotsu,Shigeo Horie,Yoshiyuki Kakehi,Seiji Naito,Norio Nonomura,Osamu Ogawa,Mototsugu Oya,Kazuhiro Suzuki,Atsushi Saito,Satoshi Uno,Hideyuki Akaza

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 0|浏览14

暂无评分

摘要

81Background: Enzalutamide has been approved for the treatment of CRPC in Japan since 2014. This study compared the efficacy and safety of enzalutamide + ADT and flutamide + ADT in the treatment of...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要